---
canonical_name: Danshen
alternate_names: Salvia miltiorrhiza, Dan Shen, Red Sage Root, Chinese Sage, Tan Shen, Radix Salviae Miltiorrhizae, Salviae Miltiorrhizae Radix et Rhizoma
canonical_topic: Danshen for Health & Longevity
short_topic_lc: danshen
creation_date: 2026-0825-2017
creator_ai_fullname: Opus 5
ep_keywords: Traditional Chinese Medicine, TCM Herbs
---

# Danshen for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Salvia miltiorrhiza, Dan Shen, Red Sage Root, Chinese Sage, Tan Shen, Radix Salviae Miltiorrhizae, Salviae Miltiorrhizae Radix et Rhizoma

  

## Motivation

<!-- Author's statement: this motivation section was written last, after every other section of this review had been completed, so that it reflects the full scope of the evidence rather than a preliminary impression of it. -->

Danshen is the dried root of a red-flowered sage that grows across China and neighbouring regions. For two thousand years it has been used in Chinese herbal practice for problems involving the heart and circulation, and it is among the best-selling herbal products in Asia. Its appeal outside Asia rests on two families of active substances — one that dissolves in water, one that dissolves in oil — which together appear to relax blood vessels, quiet inflammation, and make platelets less prone to clumping.

The research base is unusually large in volume: thousands of trials have been run in China, most of them adding the root to standard heart medicines rather than replacing them, and a commercial drug-development programme has spent more than two decades seeking formal approval in the United States for a Danshen-based tablet for chest pain. The quality of that literature, however, varies widely, and a European trial of a plain water extract reported no benefit at all.

This review examines what the evidence shows about Danshen's reported effects, the harms and drug interactions attached to it, the preparations and doses used in practice, and how far the strength of the underlying research supports any of it.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  

## Recommended Reading

This section collects high-level overviews of Danshen that discuss the root, its constituents, or its cardiovascular use in substantial depth.

<!-- Author's statement on the search: a real-time search was performed in August 2026 across the web and PubMed for high-level Danshen overviews, and each priority platform was searched twice — by web search for "<expert name> danshen" / "<expert name> Salvia miltiorrhiza" and directly on the platform's own site search (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io). Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io returned nothing on Danshen or Salvia miltiorrhiza. Life Extension names the herb only in passing inside protocols on other conditions — one sentence in the Insomnia protocol and a single clause in the Idiopathic Pulmonary Fibrosis protocol — neither of which is an overview of Danshen, so neither meets the depth bar for this list. Systematic reviews and meta-analyses, encyclopedias and wikis, database and monograph entries (WebMD, Drugs.com, Memorial Sloan Kettering About Herbs), forums, and mainstream media were excluded. -->

* [Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics](https://pubmed.ncbi.nlm.nih.gov/29698387/) - Li et al., 2018

  The most complete single narrative overview of the root's chemistry and cardiovascular pharmacology, organised by disease target rather than by compound.

* [Danshen (Salvia miltiorrhiza Bunge): A Prospective Healing Sage for Cardiovascular Diseases](https://pubmed.ncbi.nlm.nih.gov/28828985/) - Chen & Chen, 2017

  Reviews absorption and metabolism of the phenolic acids and tanshinones alongside their effects on plaque formation, clotting, and reperfusion injury.

* [Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions](https://pubmed.ncbi.nlm.nih.gov/17302964/) - Adams et al., 2006

  An early Western appraisal that separates what animal ischaemia models showed from what the Chinese clinical literature actually demonstrated, and names the methodological gaps.

* [Danshen (Salvia miltiorrhiza) on the Global Market: What Are the Implications for Products' Quality?](https://pubmed.ncbi.nlm.nih.gov/33981218/) - Kum et al., 2021

  Surveys commercially sold Danshen products and supply chains, explaining why marker content and botanical identity differ so widely between brands.

* [Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers](https://pubmed.ncbi.nlm.nih.gov/28680091/) - Xing et al., 2017

  Human study showing how far formulation changes blood levels of the oil-soluble tanshinones, which is the central practical problem with oral Danshen.

Note: no priority platform has published an overview of Danshen. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io returned no result at all for the herb, on either a web search or their own site search. Life Extension mentions it only in passing inside protocols on unrelated conditions — a single sentence in its Insomnia protocol and one clause in its Idiopathic Pulmonary Fibrosis protocol — which is too thin to serve as a high-level overview, so the list is drawn from qualifying academic overviews instead.

  

## Grokipedia

<!-- Author's statement on the search: grokipedia.com was searched directly with the browser tool for "Salvia miltiorrhiza" and "Danshen" on 17 August 2026; the search returned 294 results, the first of which is the dedicated article "Salvia miltiorrhiza", confirmed by loading /page/Salvia_miltiorrhiza. -->

* [Salvia miltiorrhiza](https://grokipedia.com/page/Salvia_miltiorrhiza)

  Covers the plant's botany, distribution, and cultivation alongside its constituents and traditional medical use, giving botanical context that pharmacology reviews omit.

  

## Examine

<!-- Author's statement on the search: examine.com was searched directly with the browser tool for "danshen" and "Salvia miltiorrhiza" on 17 August 2026; the search returned the dedicated supplement page "Danshen" at /supplements/danshen/, which was then loaded and read. -->

* [Danshen](https://examine.com/supplements/danshen/)

  Summarises the evidence grade Examine assigns to Danshen for circulatory and heart endpoints and gives the dosing conventions used for dripping pills and tablets.

  

## ConsumerLab

<!-- Author's statement on the search: consumerlab.com was searched directly with the browser tool for "danshen" and "Salvia miltiorrhiza" on 17 August 2026. No product review, supplement encyclopedia entry, or dedicated article for Danshen exists. The only hits are general Recalls & Warnings news items in which Danshen is mentioned: a 2013 Health Canada warning about methemoglobinemia linked to Compound Danshen Dripping Pills, a 2016 report on supplements that may worsen heart failure, and a 2023 FDA warning letter to an unrelated company. -->

ConsumerLab has not tested Danshen products and has no dedicated Danshen article; the herb appears only inside general recall and warning news items, so no article link can be given.

  

## Systematic Reviews

The papers below are systematic reviews and meta-analyses — analyses that pool many randomized controlled trials (RCTs — trials in which participants are assigned to treatment or placebo by chance) — of Danshen preparations in human disease.

* [The Efficacy of Danshen Injection as Adjunctive Therapy in Treating Angina Pectoris: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/29150156/) - Shao et al., 2018

  Pools ten trials in 944 patients with chest pain; the clearest quantitative estimate of add-on benefit, with the quality caveats stated openly.

* [Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews](https://pubmed.ncbi.nlm.nih.gov/25582415/) - Luo et al., 2015

  Grades thirteen earlier reviews covering 34,071 participants and shows that pooled benefit rests on evidence rated very low to moderate.

* [Effects and safety of Salvia miltiorrhiza on the improvement of renal function, inflammatory factors, and vascular endothelium in patients with diabetic kidney disease: a meta-analysis and systematic review](https://pubmed.ncbi.nlm.nih.gov/41019991/) - Zheng et al., 2025

  The only pooled analysis of Danshen used alone rather than in mixtures; covers kidney, inflammation, and vessel-lining endpoints plus adverse-event rates.

* [Clinical efficacy of Danshen preparation in the treatment of vascular cognitive impairment: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36742208/) - Li et al., 2022

  Pools twelve trials in 1,316 patients with circulation-related cognitive decline, reporting both cognitive scores and inflammatory markers.

* [Effectiveness and Safety of Fufang Danshen Dripping Pill (Cardiotonic Pill) on Blood Viscosity and Hemorheological Factors for Cardiovascular Event Prevention in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/37893448/) - Wi et al., 2023

  Independent Korean team pooling eighteen trials in 1,532 diabetic patients on blood-thickness endpoints, with adverse events tabulated.

Trade-off coverage: reviews of the claimed effect are plentiful, but Danshen's principal risk — bleeding and interaction with anticoagulant and antiplatelet drugs — has no systematic review or meta-analysis of its own; that risk is documented only in case series and pharmacokinetic studies, and safety appears in the reviews above solely as adverse-event counts inside efficacy analyses.

**Conflict of interest:** most of this literature was produced in China by institutions and companies with a direct commercial stake in Danshen products, above all Tasly Pharmaceuticals, which manufactures the Compound Danshen Dripping Pill assessed in the second and fifth papers and sponsors the ongoing Western approval programme; the negative trials cited later in this review come from investigator-initiated European work with no product sponsor.

  

## Mechanism of Action

Danshen root contains two chemically opposite groups of actives. The water-soluble phenolic acids — tanshinol (danshensu), salvianolic acid B, and rosmarinic acid — dominate aqueous extracts. The oil-soluble diterpene quinones — tanshinone IIA, tanshinone I, and cryptotanshinone — dominate alcohol extracts and give the root its colour.

Both groups converge on the vessel wall. Phenolic acids raise nitric oxide (a gas the vessel lining makes to relax blood vessels) by activating endothelial nitric oxide synthase (eNOS — the enzyme that produces it), scavenge free radicals, and suppress NF-κB (a master switch that turns on inflammatory genes). Tanshinones block calcium entry into heart and smooth-muscle cells, activate Nrf2 (a switch that turns on the cell's own antioxidant genes), and inhibit platelet aggregation, the basis of the [antithrombotic effect](https://pubmed.ncbi.nlm.nih.gov/11302416/).

Pharmacologically, tanshinol has a short elimination half-life of about 0.5 hours and is [cleared largely unchanged in urine](https://pubmed.ncbi.nlm.nih.gov/18474682/), while the lipophilic tanshinones distribute into tissue but have very poor oral bioavailability — [micronising the root raised tanshinone exposure five- to several-hundred-fold](https://pubmed.ncbi.nlm.nih.gov/28680091/). Metabolism involves cytochrome P450 enzymes (CYP — the liver's main drug-processing family), with [tanshinones inhibiting CYP2C9, the enzyme that clears warfarin, and modulating CYP1A2 and CYP3A4, which handle most other oral drugs](https://pubmed.ncbi.nlm.nih.gov/22718621/). Selectivity is low: no single receptor target explains the effects.

The competing reading is that human plasma tanshinone levels sit far below concentrations active in cell culture, so clinical effects may come from the phenolic acids, metabolites, or co-formulated herbs rather than tanshinones.

  

## Historical Context & Evolution

Danshen appears in the *Shennong Bencao Jing*, compiled around the first to second century CE, as a superior-grade herb used to "invigorate blood and dispel stasis". Its classical indications were menstrual disorders, abdominal masses, restlessness and insomnia, and sores — not chest pain, which entered the picture much later once stasis theory was mapped onto cardiac ischaemia.

The modern era began in 1930s–1970s China with the isolation of the tanshinones and the development of an injectable extract for acute cardiac and cerebral ischaemia. Tasly's Compound Danshen Dripping Pill, combining Danshen with *Panax notoginseng* and borneol, was launched in 1993 and became the country's best-selling herbal cardiac product. It was the first Chinese herbal medicine accepted into the United States drug-approval pathway, clearing a [Western dose-escalation tolerability study](https://pubmed.ncbi.nlm.nih.gov/23232790/) before entering late-stage trials.

Western replication has been mixed rather than simply negative. A Dutch crossover trial of a plain water extract found [no benefit on lipids, blood pressure, or vessel-lining function, with a small rise in LDL cholesterol (low-density lipoprotein, the plaque-forming cholesterol fraction)](https://pubmed.ncbi.nlm.nih.gov/26192328/). That result does not overturn the Chinese literature so much as expose what differs between the two: aqueous root extracts carry almost no tanshinones, doses were lower, and participants had no ischaemic disease to improve. Chinese reviewers, for their part, have themselves [graded the domestic evidence as very low to moderate quality](https://pubmed.ncbi.nlm.nih.gov/25582415/). The open question is therefore formulation and population, not whether one tradition has been refuted by the other.

  

## Expected Benefits

<!-- Author's statement: before writing this section a dedicated search of the complete benefit profile was performed across PubMed (systematic reviews, meta-analyses, and randomized trials of Salvia miltiorrhiza, Danshen, tanshinone, and salvianolic acid), ClinicalTrials.gov, Examine, and Grokipedia, so that benefits outside the cardiovascular core — renal, cognitive, urological, ophthalmic, and metabolic — were captured rather than assumed absent. -->

### High 🟩 🟩 🟩

#### Reduced Angina Symptom Burden as an Add-On to Standard Therapy

Danshen preparations added to conventional antianginal drugs reduce the frequency and severity of exertional chest pain and improve ischaemic changes on the electrocardiogram (ECG — a recording of the heart's electrical activity). A [meta-analysis of ten RCTs in 944 patients](https://pubmed.ncbi.nlm.nih.gov/29150156/) found consistent benefit, and an [overview of thirteen systematic reviews covering 34,071 participants](https://pubmed.ncbi.nlm.nih.gov/25582415/) reached the same direction. Individual trial quality is low, most trials are unblinded, and hard outcomes such as myocardial infarction (heart attack) or death remain unproven.

**Magnitude:** Symptom improvement odds ratio (OR — how much more likely an outcome is in one group than the other) 3.66, 95% confidence interval (CI — the range within which the true value probably lies) 2.50–5.36; ECG improvement OR 3.25, 95% CI 1.74–6.08.

### Medium 🟩 🟩

#### Blood Pressure Reduction ⚠️ Conflicted

Danshen added to existing antihypertensive treatment lowers systolic pressure, plausibly through nitric-oxide-mediated vessel relaxation. A [12-week placebo-controlled trial in 55 patients with uncontrolled hypertension](https://pubmed.ncbi.nlm.nih.gov/21887804/) and a [320-patient intravenous trial](https://pubmed.ncbi.nlm.nih.gov/40658027/) both reported meaningful falls, and a [trial in healthy smokers](https://pubmed.ncbi.nlm.nih.gov/30621047/) found lower systolic pressure with a Danshen combination. Evidence is conflicted: a [Dutch crossover trial of an aqueous root extract](https://pubmed.ncbi.nlm.nih.gov/26192328/) found no blood-pressure effect whatever, and the positive trials used richer extracts.

**Magnitude:** Systolic pressure fell 13.8 mmHg versus 4.2 mmHg on placebo over 12 weeks; blood-pressure control was achieved in 25.5% versus 7.3%.

#### Improved Kidney Function Markers in Diabetic Kidney Disease

In diabetic kidney disease, Danshen preparations reduce protein leakage and waste-product accumulation, probably by improving glomerular blood flow and damping inflammation in the kidney. The [only pooled analysis restricted to Danshen used alone, covering 21 RCTs and 1,970 patients](https://pubmed.ncbi.nlm.nih.gov/41019991/), reported improvements across filtration, inflammatory, and vessel-lining measures with no excess adverse events. Trials were short, conducted almost entirely in China, and used varied preparations, so the effect on long-term kidney survival is unknown.

**Magnitude:** Pooled mean differences versus control were −26.84 (95% CI −37.56 to −16.13) for serum creatinine, −1.58 for blood urea nitrogen (BUN — a waste product filtered by the kidney), −29.93 for 24-hour urinary protein and −4.47 for C-reactive protein; interleukin-6 and tumour necrosis factor alpha (both inflammatory signalling proteins) fell likewise.

#### Lowered Blood Viscosity and Improved Blood Flow Properties ⚠️ Conflicted

Danshen thins the blood in the rheological sense — it lowers the resistance of blood to flow — through reduced red-cell aggregation and platelet activity. An [independent Korean meta-analysis of 18 RCTs in 1,532 patients with type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/37893448/) found consistent falls in viscosity at both low and high shear together with lower homocysteine and higher adiponectin. Evidence conflicts: the [Dutch water-extract trial](https://pubmed.ncbi.nlm.nih.gov/26192328/) found no viscosity change. Viscosity is also a surrogate rather than a clinical endpoint.

**Magnitude:** Low-shear viscosity fell by a mean difference of 2.74 units (95% CI −3.77 to −1.72), high-shear viscosity by 0.86, and plasma viscosity by 0.37 versus control.

#### Slowed Progression of Early Diabetic Retinopathy

In non-proliferative diabetic retinopathy — the early stage of diabetic damage to the retina — Danshen preparations reduce retinal bleeding and microaneurysms (tiny bulges in retinal capillaries) and improve vision, plausibly by easing microvascular leakage and occlusion. A [meta-analysis of 26 RCTs in 2,047 patients](https://pubmed.ncbi.nlm.nih.gov/36120120/) graded the evidence moderate to very low. Every trial was Chinese and the analysis was written by staff of Tasly Pharmaceuticals, which makes the product tested, so independent replication is absent.

**Magnitude:** Pooled risk ratio 0.54 (95% CI 0.40–0.73) on the composite clinical-response endpoint; retinal microaneurysm counts fell by 3.74 and retinal haemorrhage scores by 0.62 versus control, with visual acuity 0.14 higher.

### Low 🟩

#### Cognitive and Functional Gains in Circulation-Related Cognitive Impairment

Danshen preparations improved cognitive scores, disability, and daily-living scores in vascular cognitive impairment (thinking decline caused by impaired brain blood flow), alongside falls in inflammatory markers, across [12 RCTs in 1,316 patients](https://pubmed.ncbi.nlm.nih.gov/36742208/). All trials were Chinese, short, and of poor methodological quality.

**Magnitude:** Mini-Mental State Examination scores 2.09 points higher (95% CI 0.33–3.84) and stroke-scale deficit scores 2.91 points lower than control.

#### Relief of Male Lower Urinary Tract Symptoms

A standardised root extract improved urinary symptom scores and erectile function versus placebo in a [12-week multicentre trial in 136 men](https://pubmed.ncbi.nlm.nih.gov/39796461/), without changing prostate-specific antigen or testosterone. A [later 12-week pilot](https://pubmed.ncbi.nlm.nih.gov/42280395/) compared the same extract with saw palmetto. Single-programme evidence, industry-linked, and not yet independently replicated.

**Magnitude:** Total International Prostate Symptom Score fell 4.40 points on 400 mg and 5.03 points on 800 mg daily against 1.06 points on placebo over 12 weeks, with erectile-function scores improving most at 400 mg.

#### Improved Pumping Function in Heart Failure

Added to guideline heart-failure therapy, Danshen decoction improved ejection fraction, chamber dimensions, and natriuretic peptides across [nine RCTs in 855 patients](https://pubmed.ncbi.nlm.nih.gov/37146072/). Evidence quality was graded moderate to low and no trial reported adverse events, which itself signals incomplete reporting.

**Magnitude:** Left ventricular ejection fraction (the share of blood the heart ejects per beat) rose 5.46 percentage points and B-type natriuretic peptide fell 88.6 pg/mL versus conventional treatment alone.

#### Fewer Recurrent Ischaemic Strokes

A [one-year controlled pilot in 106 patients](https://pubmed.ncbi.nlm.nih.gov/19449344/) after ischaemic stroke or transient ischaemic attack (TIA — a temporary blockage of brain blood flow) linked a Danshen dripping pill to fewer recurrences and lower C-reactive protein. Brain bleeding was not increased. Allocation followed enrolment period, not randomisation, leaving confounding likely.

**Magnitude:** Recurrent stroke or TIA occurred in 9.6% of treated patients versus 24.1% of controls over one year.

### Speculative 🟨

#### Protection Against Chemotherapy-Related Heart Damage

Danshen constituents reduced anthracycline-induced cardiac injury in animal models, per a [systematic review of preclinical studies](https://pubmed.ncbi.nlm.nih.gov/41138578/). No adequately powered human trial has tested whether cardiac function is preserved.

#### Slowing of Atherosclerotic Plaque Progression

[Pooled animal work](https://pubmed.ncbi.nlm.nih.gov/41690432/) suggests Danshen constituents reduce plaque area and stabilise lesions. The basis is entirely preclinical: no human imaging or outcome trial has measured plaque change with Danshen.

  

## Benefit-Modifying Factors

* **Baseline symptom and inflammation burden:** benefit concentrates in people with active ischaemic symptoms or raised inflammatory markers; the [Dutch trial in volunteers with no ischaemic disease](https://pubmed.ncbi.nlm.nih.gov/26192328/) found nothing to improve.

* **Baseline blood pressure and viscosity:** larger absolute falls occur when starting systolic pressure is above 140 mmHg or blood viscosity is elevated; near-normal starting values leave little room for measurable change.

* **CYP2C9 and epoxide hydrolase variants:** these genes govern warfarin handling, and carriers show different responses when Danshen is [co-administered with warfarin](https://pubmed.ncbi.nlm.nih.gov/37214448/), which shifts both the interaction risk and the observed anticoagulant effect.

* **Sex:** renal excretion of tanshinol is [significantly greater in women than in men](https://pubmed.ncbi.nlm.nih.gov/18474682/) after body-weight correction, implying shorter systemic exposure to the main water-soluble marker in women.

* **Age:** most trials enrolled patients with a median age near 60; older adults with reduced kidney function clear tanshinol more slowly, raising exposure, while polypharmacy raises interaction risk in the same group.

* **Pre-existing conditions:** diabetes, chronic kidney disease, and established coronary disease define the populations in which benefit has actually been measured; healthy users have essentially no supporting outcome data.

  

## Potential Risks & Side Effects

<!-- Author's statement: before writing this section a dedicated side-effect search was performed across drug reference sources (Drugs.com, WebMD, Memorial Sloan Kettering About Herbs, Health Canada and FDA advisories) and PubMed case reports, pharmacovigilance studies, and post-marketing surveillance, so that interaction hazards and rare events were captured rather than inferred from trial adverse-event tables alone. -->

### High 🟥 🟥 🟥

#### Increased Bleeding Risk and Potentiation of Anticoagulants ⚠️ Conflicted

Danshen inhibits platelet aggregation, interferes with the clotting cascade, and shows antithrombin-like activity; it also slows warfarin clearance and prolongs its half-life. Published cases describe [gross over-anticoagulation and bleeding when Danshen was added to stable warfarin therapy](https://pubmed.ncbi.nlm.nih.gov/11302416/), while a monitored clinical study found [warfarin concentrations varying with genotype but no significant dose change and no bleeding](https://pubmed.ncbi.nlm.nih.gov/31053296/). The hazard is pharmacokinetic and pharmacodynamic at once, and it is the single reason most references advise against combining the two.

**Magnitude:** Case reports document international normalised ratio (INR — a standardised measure of how long blood takes to clot) rising above 5 with haemorrhage; in rats Danshen raised warfarin peak concentration and area under the curve while reducing clearance.

### Medium 🟥 🟥

#### Hypersensitivity and Infusion Reactions with Injectable Preparations

The injectable and infusion forms used in Chinese hospitals — not sold as supplements in the West — carry rash, fever, palpitations, and occasional anaphylaxis (a severe, whole-body allergic reaction). A [prospective surveillance cohort of 30,180 inpatients](https://pubmed.ncbi.nlm.nih.gov/28125608/) quantified this and identified male sex, more concomitant drugs, longer therapy, higher concentration, and unapproved solvents as risk factors. Nine reaction types were not on the approved label. Oral preparations do not carry this profile.

**Magnitude:** Adverse events occurred in 6.40% of patients, drug-related events in 1.57%, and formally adjudicated adverse drug reactions in 0.79%.

#### Falsely Altered Serum Digoxin Measurements

Danshen constituents cross-react with several digoxin immunoassays (laboratory tests that detect a drug using antibodies), producing [both falsely high and falsely low serum digoxin values](https://pubmed.ncbi.nlm.nih.gov/11554169/) depending on the assay platform. The consequence is misdosing of a narrow-margin heart drug rather than direct toxicity. Measuring free digoxin, or using a chemiluminescent assay, [removes the interference](https://pubmed.ncbi.nlm.nih.gov/17164693/).

**Magnitude:** Interference runs in both directions and its size varies by assay brand and even between batches of the same herbal product; the literature reports no clinical event rate attached to it.

#### Gastrointestinal Intolerance and Dizziness

The commonest complaints with oral and intravenous Danshen are stomach discomfort, nausea, and dizziness, the last plausibly reflecting blood-pressure lowering. In a [320-patient hypertension trial](https://pubmed.ncbi.nlm.nih.gov/40658027/) these were mild to moderate and caused no dropouts, and a [136-man urological trial](https://pubmed.ncbi.nlm.nih.gov/39796461/) reported no serious adverse events leading to discontinuation. Reporting quality across the wider Chinese literature is poor, so true rates are likely understated.

**Magnitude:** In a [Western tolerability study](https://pubmed.ncbi.nlm.nih.gov/23232790/) these symptoms occurred in 3.3% of participants overall and in 38.9% of those given more than four times a regular therapeutic dose; in the 320-patient trial they were mild to moderate, with 94.2% of participants completing at least 80% of the protocol.

### Low 🟥

#### Excessive Blood Pressure Lowering with Antihypertensive Drugs

Danshen lowers systolic pressure on top of existing therapy, by [13.8 mmHg versus 4.2 mmHg on placebo](https://pubmed.ncbi.nlm.nih.gov/21887804/). In people already near target, the same effect that counts as a benefit becomes a hazard, with light-headedness on standing as the practical consequence.

**Magnitude:** Additional systolic reduction of roughly 10 mmHg beyond placebo, with pulse rate also falling by about 3 beats per minute versus a small rise on placebo.

#### Inconsistent Exposure from Variable Product Quality

Commercial Danshen products differ widely in marker content, botanical identity, and supply chain, as documented in a [global market survey](https://pubmed.ncbi.nlm.nih.gov/33981218/). The risk is receiving far more or far less active material than the trials used, including near-zero tanshinone content in water-only extracts.

**Magnitude:** Marker content and botanical identity vary widely between commercial products; the literature reports no outcome figure linking a given degree of variation to a clinical result.

#### Adverse LDL Cholesterol Change with Aqueous Extracts ⚠️ Conflicted

A [randomised crossover trial](https://pubmed.ncbi.nlm.nih.gov/26192328/) found that four weeks of a water-based root extract slightly raised LDL cholesterol, with no offsetting change in other markers. This directly conflicts with a [12-week intravenous trial](https://pubmed.ncbi.nlm.nih.gov/40658027/) reporting falls in total cholesterol, LDL, and triglycerides; formulation and route differ completely between the two.

**Magnitude:** LDL cholesterol 3.82 mmol/L on Danshen versus 3.52 mmol/L on placebo (about +12 mg/dL); the opposing trial reported an LDL fall of 10.7%.

### Speculative 🟨

#### Methemoglobinemia

Health Canada linked one case of methemoglobinemia (a disorder in which blood cannot release oxygen) to a Compound Danshen Dripping Pill in 2013. The basis is a single case report with no controlled data.

#### Altered Exposure to Other Liver-Metabolised Drugs

Beyond warfarin, tanshinones modulate several CYP enzymes in laboratory and animal work, so exposure to drugs such as statins, midazolam, or ciclosporin could shift. No human interaction study has confirmed a clinically relevant change.

  

## Risk-Modifying Factors

* **CYP2C9, VKORC1, and epoxide hydrolase variants:** these determine warfarin sensitivity, and the Danshen–warfarin interaction [tracks with epoxide hydrolase genotype](https://pubmed.ncbi.nlm.nih.gov/37214448/), which shifted clotting-factor expression in carriers although the measured effect on warfarin itself was slight.

* **Baseline INR, platelet count, and haemoglobin:** a starting INR already near the top of range, platelets below 100 × 10⁹/L, or anaemia all convert Danshen's mild antiplatelet effect into a clinically meaningful bleeding hazard.

* **Sex:** men showed a significantly higher adverse-event rate than women in the [30,180-patient infusion cohort](https://pubmed.ncbi.nlm.nih.gov/28125608/), while women clear the main water-soluble marker faster, so exposure and reaction risk differ in opposite directions.

* **Pre-existing conditions:** peptic ulcer disease, recent haemorrhagic stroke, uncontrolled hypotension, and severe hepatic or renal impairment each amplify either bleeding risk or drug accumulation.

* **Age:** adults above roughly 70 combine reduced renal clearance, more concomitant drugs — an independent risk factor in the surveillance cohort — and higher baseline bleeding risk, making them the group most exposed to interaction harm.

  

## Key Interactions & Contraindications

* **Warfarin (absolute caution; avoid combination):** additive anticoagulation plus reduced warfarin clearance produces INR elevation and bleeding. Where the combination is unavoidable, published practice is weekly INR checks until stable, with the warfarin dose reduced accordingly.

* **Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) — caution:** additive bleeding risk by pharmacodynamic overlap; no interaction data exist, so combination is generally avoided rather than monitored.

* **Antiplatelet drugs (aspirin, clopidogrel, ticagrelor) — caution:** additive platelet inhibition raising bruising and gastrointestinal bleeding risk; mitigation is avoidance of triple therapy and prompt reporting of unusual bleeding.

* **Digoxin — monitor:** Danshen distorts common digoxin immunoassays in both directions. Mitigation is to measure free digoxin or use a chemiluminescent assay before any dose change.

* **Antihypertensives (amlodipine, lisinopril, losartan, thiazides) — monitor:** additive blood-pressure lowering with light-headedness; mitigation is home blood-pressure monitoring during the first 4 weeks.

* **CYP3A4 and CYP2C9 substrates (simvastatin, midazolam, ciclosporin) — caution:** tanshinones alter these enzymes in preclinical work, potentially changing drug levels; separating doses and watching for exaggerated drug effects is the practical response.

* **Over-the-counter NSAIDs (non-steroidal anti-inflammatory painkillers such as ibuprofen, naproxen, and high-dose aspirin) — caution:** additive gastrointestinal bleeding risk; mitigation is paracetamol for routine analgesia while Danshen is taken.

* **Bleeding-prone supplements (fish oil, ginkgo, garlic, nattokinase, high-dose vitamin E, curcumin) — caution:** additive antiplatelet effect; mitigation is not stacking more than one such agent and stopping all of them 1–2 weeks before surgery.

* **Co-formulated herbs (*Panax notoginseng*, borneol, *Panax ginseng*) — monitor:** most studied products are mixtures, so effects and interactions attributed to Danshen may belong to partners; the label, not the herb name, identifies what a product actually contains.

* **Other interventions — monitor:** during eccentric resistance training a Danshen–ginseng combination [abolished the gain in muscle mass](https://pubmed.ncbi.nlm.nih.gov/27912940/) that training otherwise produced, so timing relative to hypertrophy blocks matters.

**Populations who should avoid Danshen:**

* Anyone taking warfarin or another anticoagulant, or with an inherited bleeding disorder such as haemophilia or platelets below 100 × 10⁹/L  
* Pregnancy and breastfeeding — classical texts treat the root as blood-moving and it is traditionally contraindicated in pregnancy  
* Within 2 weeks of any scheduled surgery, dental extraction, or spinal procedure  
* Active peptic ulcer or gastrointestinal bleeding within the previous 90 days  
* Haemorrhagic stroke within the previous 90 days, or an untreated intracranial aneurysm  
* Symptomatic hypotension with systolic pressure below 100 mmHg  
* Severe hepatic impairment (Child-Pugh Class C — the most advanced grade of liver failure)

  

## Risk Mitigation Strategies

* **Anticoagulant screen before starting:** protocols open by establishing that no warfarin, direct oral anticoagulant, or dual antiplatelet therapy is in use; this removes the one interaction responsible for the documented serious harms.

* **Staggered introduction with INR checks:** where an anticoagulant genuinely cannot be stopped, INR measured at baseline, day 7, and day 14 after adding Danshen catches over-anticoagulation before bleeding occurs.

* **Low starting dose with slow titration:** protocols start at the lower end of the studied range — for example 400 mg standardised extract daily for 2 weeks before 800 mg is considered — limiting dizziness and gastrointestinal upset.

* **Home blood-pressure monitoring for 4 weeks:** seated pressure taken twice daily during introduction detects additive hypotension in anyone already on antihypertensive drugs.

* **Pre-surgical washout:** stopping Danshen at least 14 days before any planned surgery, dental extraction, or spinal procedure reverses the platelet effect and avoids perioperative bleeding.

* **Free-digoxin testing:** in anyone on digoxin, a free-digoxin or chemiluminescent assay keeps assay interference from triggering a mistaken dose change.

* **Single-agent stacking rule:** combining Danshen with other platelet-inhibiting supplements such as fish oil, ginkgo, or nattokinase compounds bleeding risk without added evidence of benefit.

* **Oral rather than injectable forms:** the serious hypersensitivity events cluster in infusion preparations used in hospital settings, which have no place in self-directed use.

  

## Therapeutic Protocol

* **Standard crude-root dose:** Chinese Pharmacopoeia practice uses 9–15 g of dried root daily as a decoction, the reference point from which most product doses are derived.

* **Compound dripping pill protocol:** the most-studied product is taken as 10 pills three times daily, sublingually or swallowed, the regimen used across the coronary trials.

* **Standardised extract protocol:** capsule trials used 1,000 mg twice daily for hypertension and 400–800 mg daily of a root extract for urinary symptoms, the two clearest oral dose anchors.

* **Competing approaches:** the Chinese integrative model adds Danshen to antianginal therapy, while Western product development pursues a single standardised tablet as monotherapy for chest pain; neither has been shown superior.

* **Attribution of approaches:** the dripping-pill model was popularised by Tasly Pharmaceuticals in Tianjin; the Western standardised-extract model comes from Korean and European supplement developers.

* **Half-life and dose splitting:** tanshinol's elimination half-life is roughly 0.5 hours and tanshinone exposure is erratic, so split dosing two to three times daily is standard rather than a single daily dose.

* **Time of day:** doses are conventionally taken morning and evening with meals; dietary fat aids absorption of the oil-soluble tanshinones and food reduces gastrointestinal upset.

* **Genetic considerations:** CYP2C9, VKORC1, and epoxide hydrolase variants matter only for those on warfarin, where they change the size of the interaction rather than the Danshen dose itself.

* **Sex differences:** women excrete tanshinol faster after body-weight correction, which argues for split rather than once-daily dosing, though no trial has tested sex-specific regimens.

* **Age considerations:** trial populations centred near age 60; in adults over 75 the lower end of each range is the sensible anchor because of slower clearance and higher interaction load.

* **Baseline biomarkers:** raised blood pressure, blood viscosity, or C-reactive protein identify those in whom measurable change has been demonstrated; normal values predict little detectable response.

* **Pre-existing conditions:** diabetes, chronic kidney disease, and coronary disease define the trial populations, so protocols are anchored in those groups rather than in healthy users.

  

## Discontinuation & Cycling

* **Intended duration:** trials ran 4–24 weeks and the Chinese clinical model treats Danshen as continuous adjunctive therapy for chronic vascular disease rather than a short course.

* **Withdrawal effects:** none documented. No trial has reported rebound angina, blood-pressure rebound, or any withdrawal syndrome after stopping.

* **Tapering:** not required pharmacologically given the short half-life; abrupt discontinuation is the norm in every published trial protocol.

* **Planned interruption before procedures:** a deliberate 14-day stop before surgery or dental work is the one discontinuation rule with a clear rationale — reversal of platelet inhibition.

* **Cycling:** no evidence supports cycling. Tolerance has not been demonstrated, and no trial has compared intermittent with continuous dosing.

  

## Sourcing and Quality

* **Standardisation markers:** products stating salvianolic acid B content of at least 3% and tanshinone IIA of at least 0.2% meet the Chinese Pharmacopoeia minima; unstandardised "root powder" tells the buyer nothing.

* **Extraction method matters most:** water extracts carry the phenolic acids but almost no tanshinones, while alcohol or supercritical extracts carry both; the negative European trial used a water extract.

* **Botanical identity:** related species such as *Salvia przewalskii* and *Salvia bowleyana* are substituted in commerce, so a certificate of analysis identifying *Salvia miltiorrhiza* specifically is the marker that separates verified material from substituted material.

* **Heavy metals:** the root readily accumulates cadmium and lead from soil, making batch-level heavy-metal testing more important for Danshen than for most botanicals.

* **Third-party testing:** independent verification such as USP (United States Pharmacopeia), NSF, or Eurofins certification, plus a published certificate of analysis, is the practical proxy for the identity and contaminant checks a buyer cannot perform.

* **Reputable formats:** the Compound Danshen Dripping Pill from Tasly is the product with by far the most clinical data behind it, though it is a multi-herb mixture rather than pure Danshen.

  

## Practical Considerations

* **Time to effect:** symptom endpoints in the angina and hypertension trials moved by 2–4 weeks; blood viscosity, inflammatory, and kidney markers took 8–12 weeks to separate from control.

* **Common pitfall — wrong extract:** buying a water-based extract and expecting tanshinone-mediated effects is the single most frequent mismatch between what is purchased and what was studied.

* **Common pitfall — substitution for real therapy:** every positive trial added Danshen to guideline treatment; none tested it as a replacement for antianginal, antihypertensive, or antiplatelet drugs.

* **Common pitfall — ignoring anticoagulants:** the documented serious harms come almost entirely from people who added Danshen to warfarin without telling a clinician or checking clotting.

* **Regulatory status:** in the United States Danshen is sold as a dietary supplement with no approved drug indication; the compound dripping pill remains investigational there while being a licensed medicine in China.

* **Cost and accessibility:** at roughly $10–25 per month Danshen is inexpensive and widely available online, far cheaper than the drugs and procedures it is positioned alongside.

* **Payer incentives:** no Western insurer reimburses Danshen, so no institutional payer gains from promoting or suppressing it; in China, reimbursement of the branded dripping pill aligns payer and manufacturer interests.

  

## Interaction with Foundational Habits

* **Sleep:** indirect and mild. Classical use included restlessness and palpitations, but no trial has measured sleep quality, and the root has no sedative constituent; evening dosing has not been shown to disturb or improve sleep.

* **Nutrition:** potentiating. Dietary fat improves absorption of the oil-soluble tanshinones, so doses are best taken with a meal containing fat; no nutrient depletion has been described, and no food needs to be avoided.

* **Exercise:** potentially blunting. In a [12-week eccentric resistance training trial in middle-aged and older adults](https://pubmed.ncbi.nlm.nih.gov/27912940/), a Danshen–ginseng combination abolished the training-induced gain in muscle mass, arguing for separation from hypertrophy-focused training blocks.

* **Stress management:** indirect. Danshen lowers inflammatory markers such as C-reactive protein and interleukin-6, which overlap with stress physiology, but no study has measured cortisol or a stress-response endpoint directly, so no timing guidance follows.

  

## Monitoring Protocol & Defining Success

Before starting, the informative baseline set is a clotting panel and full blood count, blood pressure, a lipid panel, liver enzymes, kidney function with urine albumin, and high-sensitivity C-reactive protein — the last because inflammatory burden predicts who has measurable room to improve. Anyone on warfarin or digoxin needs a baseline INR or free-digoxin level before the first dose, since these are the two interactions with documented clinical consequences. Ongoing monitoring is cadence-driven rather than continuous: blood pressure at home twice daily for the first 4 weeks, clotting and full blood count at 4 weeks, then the full panel at 12 weeks and every 6–12 months thereafter while use continues. Success is defined by movement in the tracked markers plus the qualitative changes below, not by adherence itself.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| INR | 0.9–1.1 if not anticoagulated; individual target (usually 2.0–3.0) if on warfarin | Detects the main interaction hazard | INR = international normalised ratio, a standardised clotting time; conventional labs report anything under 1.2 as normal, which hides a drift upward from an individual's own baseline |
| Platelet count | 175–250 × 10⁹/L | Contextualises added antiplatelet effect | Conventional range is 150–400 × 10⁹/L; values under 100 × 10⁹/L are a reason not to use Danshen at all |
| Haemoglobin | 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women) | Detects occult blood loss | Best paired with ferritin; a fall of more than 1 g/dL without explanation is the threshold at which use is discontinued in practice |
| Blood pressure | 110–120 / 70–75 mmHg | Captures the most reproducible measured effect | Seated home readings, morning and evening, after 5 minutes' rest; office readings are too noisy for a 10 mmHg signal |
| hs-CRP | < 1.0 mg/L | Tracks the inflammatory pathway Danshen acts on | hs-CRP = high-sensitivity C-reactive protein, a general marker of body-wide inflammation; invalid within 2 weeks of infection or injury |
| LDL-C | < 100 mg/dL, or < 70 mg/dL with established coronary disease | Detects the adverse lipid signal seen with water extracts | LDL-C = low-density lipoprotein cholesterol; requires 10–12 hour fast for an accurate paired triglyceride value |
| ALT | < 25 U/L (men), < 20 U/L (women) | Screens for hepatic irritation | ALT = alanine aminotransferase, a liver enzyme; conventional upper limits near 40–55 U/L are far looser than the functional target |
| eGFR and urine albumin-to-creatinine ratio | eGFR > 90 mL/min/1.73 m²; ratio < 10 mg/g | Tracks the kidney endpoints where benefit was measured | eGFR = estimated glomerular filtration rate, a calculated measure of kidney filtering; first-morning urine preferred for the ratio |
| HbA1c | 4.8–5.4% | Contextualises use in diabetic kidney and viscosity trials | HbA1c = glycated haemoglobin, average blood sugar over about 3 months; unaffected by fasting, so it can be drawn at any time |
| Free digoxin | 0.5–0.9 ng/mL in heart failure; no separate free-digoxin target is established, so track against the individual's own pre-Danshen level | Bypasses assay interference | Only relevant for digoxin users; standard total-digoxin immunoassays are unreliable while Danshen is being taken |

Qualitative markers worth tracking:

* Frequency and severity of exertional chest tightness or breathlessness  
* Exercise tolerance — distance or workload before symptoms appear  
* Light-headedness on standing, which signals additive blood-pressure lowering  
* Unusual bruising, gum bleeding, or prolonged bleeding from small cuts  
* Cold hands and feet, a traditional proxy for peripheral circulation  
* General energy and mental clarity across the day

  

## Emerging Research

* **Late-stage Western approval trial:** [NCT03789552](https://clinicaltrials.gov/study/NCT03789552) is a phase 3 trial of the Danshen-based tablet T89 in 765 patients with chronic stable angina, running to late 2026. It is sponsored by the manufacturer, Tasly Pharmaceuticals, which is the strongest single test of the anti-anginal claim and also its largest conflict of interest.

* **Microvascular angina:** [NCT06092736](https://clinicaltrials.gov/study/NCT06092736) is a phase 4 trial of the Compound Danshen Dripping Pill in 100 patients with microvascular angina, a form of chest pain with normal large arteries where standard drugs often fail.

* **Diabetic microvascular angina:** [NCT06727890](https://clinicaltrials.gov/study/NCT06727890) extends the same product to 162 patients with diabetic microvascular angina at phase 4, testing whether the metabolic and coronary signals converge in one population.

* **Coronary microcirculation after stenting:** [NCT07621107](https://clinicaltrials.gov/study/NCT07621107) is a phase 2 trial of a Danshen-containing tablet in 70 patients, measuring microvascular function after emergency stenting for myocardial infarction.

* **Formulation science could raise or lower the case:** human work showing [tanshinone exposure rises five- to several-hundred-fold with micronisation](https://pubmed.ncbi.nlm.nih.gov/28680091/) (Xing et al., 2017) and [nano-delivery development](https://pubmed.ncbi.nlm.nih.gov/38489891/) (Jia et al., 2024) suggest current oral products may be underdosed — or that past positive results cannot be attributed to tanshinones at all.

* **Evidence that could weaken the case:** the [null crossover trial of an aqueous extract](https://pubmed.ncbi.nlm.nih.gov/26192328/) (van Poppel et al., 2015) and the [very low to moderate quality grading of the Chinese review base](https://pubmed.ncbi.nlm.nih.gov/25582415/) (Luo et al., 2015) both point to the possibility that pooled benefit reflects trial design rather than pharmacology.

* **Preclinical atherosclerosis work:** a [pooled analysis of animal studies](https://pubmed.ncbi.nlm.nih.gov/41690432/) (Zhang et al., 2026) reports plaque reduction with Danshen constituents; whether this translates to human imaging endpoints is untested and would be the natural bridge to a hard-outcome trial.

  

## Conclusion

Danshen is a traditional Chinese root remedy whose case rests on a very large but uneven body of clinical research. The most consistent signal is symptom relief in stable chest pain when the root is added to standard heart medicines, together with smaller changes in blood pressure, blood thickness, kidney and eye measures in diabetes, thinking scores after impaired brain blood flow, and urinary symptoms in men. Almost all of that work comes from Chinese hospitals and from the companies that make and sell the products, and the trials are typically small, briefly reported, and short. The one carefully controlled European study, using a simple water extract, found nothing at all. Direction of effect repeats often enough to be interesting; size of effect, and any change in survival or heart attacks, remain unsettled.

The main hazard is bleeding. The root thins the blood on its own and, in published cases, has pushed people already taking blood-thinning drugs into dangerous over-thinning. It can also distort a common heart-drug blood test, add to the effect of blood-pressure medicines, and cause stomach upset or dizziness. What is in the bottle varies widely between brands, so a product may not match what was studied.

Taken together, the picture is of a cheap and generally well-tolerated add-on with one genuine interaction hazard, plausible short-term effects on symptoms and blood-flow measures, and an evidence base whose funding and quality invite caution rather than confidence.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**